BRIEF published on 07/24/2024 at 12:35, 2 years 3 months ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Merger Financing Nasdaq Biopharmaceutical QTORIN™
BRIEF published on 07/24/2024 at 12:35, 2 years 3 months ago Palvella Therapeutics et Pieris Pharmaceuticals annoncent un accord de fusion définitif Financement Nasdaq Biopharmaceutique Fusionnement QTORIN™
PRESS RELEASE published on 07/24/2024 at 12:30, 2 years 3 months ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. announce a merger to focus on rare genetic skin diseases with QTORIN™ rapamycin. Joint webcast on July 24 at 8:30am ET Merger Clinical-stage Genetic Skin Diseases QTORIN™ Rapamycin FDA-approved Therapies
BRIEF published on 04/19/2024 at 18:15, 2 years 6 months ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Reverse Stock Split Nasdaq Compliance Financial Regulation Pieris Pharmaceuticals Stock Adjustment
BRIEF published on 04/19/2024 at 18:15, 2 years 6 months ago Pieris Pharmaceuticals annonce un regroupement d'actions de 1 pour 80 Réglementation Financière Pieris Pharmaceutique Regroupement D'actions Inversé Conformité NASDAQ Ajustement Des Stocks
PRESS RELEASE published on 04/19/2024 at 18:10, 2 years 6 months ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Pieris Pharmaceuticals, Inc. announces a 1-for-80 reverse stock split effective on April 22, 2024, to comply with Nasdaq listing requirements. No fractional shares will be issued Reverse Stock Split Compliance Nasdaq Pieris Pharmaceuticals Stockholder Ownership
BRIEF published on 03/27/2024 at 13:05, 2 years 7 months ago Pieris Pharmaceuticals Announces New Strategy to Maximize Financial Potential Shareholder Value Pieris Pharmaceuticals Strategic Reorganization Milestone Payments Royalty Potential
BRIEF published on 03/27/2024 at 13:05, 2 years 7 months ago Pieris Pharmaceuticals annonce une nouvelle stratégie pour maximiser le potentiel financier Valeur Pour Les Actionnaires Pieris Pharmaceutique Réorganisation Stratégique Paiements D'étape Potentiel De Redevances
PRESS RELEASE published on 03/27/2024 at 13:00, 2 years 7 months ago Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential Pieris Pharmaceuticals, Inc. announces strategic repositioning to maximize milestone and royalty potential from immuno-oncology assets. Cost-saving measures extend cash runway into 2027 Strategic Repositioning Cost-saving Measures Pieris Pharmaceuticals Milestone Payments Immuno-oncology Assets
Published on 11/05/2026 at 08:00, 59 minutes ago Caledonia Mining Corporation Plc: Caledonia Group Signs US$150 Million Interim Financing Facilities Agreement to Support Construction of the Bilboes Gold Project
Published on 11/04/2026 at 23:10, 9 hours 49 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 9 hours 59 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 10 hours 44 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/05/2026 at 08:45, 14 minutes ago Wyden Expands Its Offering with New Digital Asset Accounting Solution for Banks, Brokers, and Financial Institutions
Published on 11/05/2026 at 08:35, 24 minutes ago statworx Introduces Generative Site Search: Transforming Websites into Personalized AI Experiences
Published on 11/05/2026 at 08:30, 29 minutes ago FRIWO experiences persistent market weakness in financial results – positive growth momentum from order backlog and project pipeline
Published on 11/05/2026 at 08:30, 29 minutes ago Energiekontor AG: Energiekontor commissions two wind parks in Elsdorf on schedule – positive contribution to earnings for 2026
Published on 11/05/2026 at 08:07, 51 minutes ago Leifheit AG publishes its Q3 2026 quarterly statement and accelerates the FOCUS performance program
Published on 11/05/2026 at 07:00, 1 hour 59 minutes ago Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 07:00, 1 hour 59 minutes ago Eurazeo’s European asset management platform continues to gain momentum, driven by sustained international fundraising
Published on 11/05/2026 at 07:00, 1 hour 59 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
